Cited 0 times in
Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고형준 | - |
dc.contributor.author | 김용민 | - |
dc.date.accessioned | 2014-12-19T16:23:18Z | - |
dc.date.available | 2014-12-19T16:23:18Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0002-9394 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89431 | - |
dc.description.abstract | PURPOSE: To evaluate the association between improvement of photoreceptor integrity and visual acuity (VA) after anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD). DESIGN: Retrospective, cross-sectional study. METHODS: Eighty-seven eyes of 84 patients who were newly diagnosed with neovascular AMD and treated with anti-VEGF injections were reviewed retrospectively. Using spectral-domain optical coherence tomography, the status of the inner segment/outer segment photoreceptor junction (IS/OS) was graded and classified into 3 groups at baseline and 1 and 2 months after 3 monthly injections. The proportion of the improved IS/OS line after treatment was analyzed and correlated with VA. RESULTS: The number of eyes in the IS/OS+ group, representing disrupted IS/OS line less than 200 μm, was increased from 9 (10%) at baseline to 33 (38%) at 1 month. There was a significant difference in the ratio of IS/OS+ group between baseline and 1 month (P < .001). Those in the IS/OS± group, showing focal disrupted IS/OS line between 200 and 800 μm, decreased from 29 (33%) to 22 eyes (25%). Improvement of the IS/OS line at 1 month compared to baseline was noted in 43 eyes (49%) and correlated with better VA (P < .016). No increase of VA was observed in 44 eyes without definite improvement. There was no significant correlation between improvement of the IS/OS line and VA from 1 to 2 months. CONCLUSIONS: Assessing the change of the photoreceptor integrity before and after treatment would be a useful indicator to predict initial response to treatment and visual prognosis in patients with neovascular AMD. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Angiogenesis Inhibitors/administration & dosage* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorescein Angiography | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Ranibizumab | - |
dc.subject.MESH | Retinal Photoreceptor Cell Inner Segment/pathology* | - |
dc.subject.MESH | Retinal Photoreceptor Cell Outer Segment/pathology* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tomography, Optical Coherence | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.subject.MESH | Visual Acuity/physiology* | - |
dc.subject.MESH | Wet Macular Degeneration/drug therapy | - |
dc.subject.MESH | Wet Macular Degeneration/physiopathology* | - |
dc.title | Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Yong Min Kim | - |
dc.contributor.googleauthor | Ji Hyun Kim | - |
dc.contributor.googleauthor | Hyoung Jun Koh | - |
dc.identifier.doi | 22541932 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00152 | - |
dc.contributor.localId | A00742 | - |
dc.relation.journalcode | J00097 | - |
dc.identifier.eissn | 1879-1891 | - |
dc.identifier.pmid | 22541932 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002939412000815 | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Aged, 80 and over | - |
dc.subject.keyword | Angiogenesis Inhibitors/administration & dosage* | - |
dc.subject.keyword | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | Cross-Sectional Studies | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Fluorescein Angiography | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Ranibizumab | - |
dc.subject.keyword | Retinal Photoreceptor Cell Inner Segment/pathology* | - |
dc.subject.keyword | Retinal Photoreceptor Cell Outer Segment/pathology* | - |
dc.subject.keyword | Retrospective Studies | - |
dc.subject.keyword | Tomography, Optical Coherence | - |
dc.subject.keyword | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.subject.keyword | Visual Acuity/physiology* | - |
dc.subject.keyword | Wet Macular Degeneration/drug therapy | - |
dc.subject.keyword | Wet Macular Degeneration/physiopathology* | - |
dc.contributor.alternativeName | Koh, Hyoung Jun | - |
dc.contributor.alternativeName | Kim, Yong Min | - |
dc.contributor.affiliatedAuthor | Koh, Hyoung Jun | - |
dc.contributor.affiliatedAuthor | Kim, Yong Min | - |
dc.citation.volume | 154 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 164 | - |
dc.citation.endPage | 173 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF OPHTHALMOLOGY, Vol.154(1) : 164-173, 2012 | - |
dc.identifier.rimsid | 31762 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.